Divis Laboratories
- All
- News
- Videos
-
Divi's Labs Shares Decline Over 6% After Q4 Earnings
Shares of Divi's Laboratories fell more than 6 per cent on Tuesday as the company's March quarter earnings failed to cheer investors. The stock dropped as much as 6.35 per cent to hit an intraday low of Rs 3,650.
-
5 Indian Stocks That Pass The Peter Lynch Filter
Long-term investing is an age-old investing practice that requires investors to invest with a long-term horizon, for example more than 7 years.
-
Sensex Up Over 500 Points, Nifty Above 17,600; Divi's Labs, NTPC Top Gainers
Merck and company's partner Ridgeback Biotherapeutics said its experimental antiviral drug molnupiravir could halve chances of dying or being hospitalised; Divi's Laboratories makes the main ingredient of the drug
-
Divi's Labs Surges 10%, Hits Record High On Merck's Positive Data For Covid Drug
Divi's Laboratories shares have so far this year advanced 38 per cent compared with Sensex which has gained 25 per cent.
-
Stocks To Watch: Bank of Baroda, Divi's Laboratories, SAIL, Affle India
Bank of Baroda reported a net profit of Rs 1,280.6 crore in the first quarter ended March 2021 against a loss of Rs 864.3 crore in the same quarter last year
-
Pharma Firm, India's Best-Performing Stock, Sees Wave of Optimistic Calls
In just about two weeks, at least four brokerages have raised their price targets on the shares of Divi's Laboratories -- one of the top producers of active pharmaceutical ingredients
-
Divi's Lab Shares Pare Gains, Trade Flat After US FDA Closes Out Warning Letter
The shares of Divi's Laboratories (Divi's Lab) pared early gains to trade 0.86% higher at Rs 1,018 on BSE at 3.10 pm. The scrip had hit 8% higher
-
Divi's Lab Shares Close 17% Higher As USFDA's Import Ban Set To Be Lifted From Vizag Plant
Divi's Laboratories has informed the NSE in a stock exchange filing that the USFDA will soon lift the import Alert 66-40 and will move to close out the warning letter issued to the company's unit-II at Vishakhapatnam.
-
Diwali Picks 2017: HDFC Securities' Five Stock Bets For Samvat 2074
For Samvat 2074, the top five stocks recommended by HDFC Securities are Bajaj Auto, Divi's Laboratories, Birla Corp, Persistent Systems and ICICI Prudential Life Insurance.
-
USFDA issues Warning Letter To Divis Labs For Vishakhapatnam Unit
The United States Food and Drug Administration (USFDA) has issued warning letter for the company's Unit-II at Vishakhapatnam, Divis Laboratories said in a BSE filing.
-
Trading Calls: Buy Pidilite Industries, Divi's Laboratories, Say Experts
Domestic brokerage Angel Broking in a note said domestic markets may see some consolidation or minor profit-taking moves but the undertone remains bullish.
-
Divis Lab Slumps 20% After US Regulator Issues Import Alert For Vizag Plant
Surjit Pal, pharma analyst at Prabhudas Lilladher, says Divis Lab shares could remain under pressure as its FY18 earnings would be hit due to the import alert.
-
Divi's Laboratories Files Response To US Regulator's Observations
Last month, the US regulator had made five observations after inspection of the company's manufacturing plant at Visakhapatnam.
-
Divi's Laboratories Slumps Over 30% In Just Two Days Over FDA Concerns
The Vizag plant is one of the biggest plants for Divi's. The company manufactures active pharmaceutical ingredients (APIs) and intermediates for generics among others at the Vizag manufacturing plant.
-
Divis Labs Q2 Net Down 24.6% At Rs 224 Crore
Divis Laboratories reported a 24.60 per cent dip in its standalone net profit to Rs 223.85 crore for the quarter ended September 30, 2016 mainly on account of increased expenses.
-
Divi's Labs Shares Decline Over 6% After Q4 Earnings
Shares of Divi's Laboratories fell more than 6 per cent on Tuesday as the company's March quarter earnings failed to cheer investors. The stock dropped as much as 6.35 per cent to hit an intraday low of Rs 3,650.
-
5 Indian Stocks That Pass The Peter Lynch Filter
Long-term investing is an age-old investing practice that requires investors to invest with a long-term horizon, for example more than 7 years.
-
Sensex Up Over 500 Points, Nifty Above 17,600; Divi's Labs, NTPC Top Gainers
Merck and company's partner Ridgeback Biotherapeutics said its experimental antiviral drug molnupiravir could halve chances of dying or being hospitalised; Divi's Laboratories makes the main ingredient of the drug
-
Divi's Labs Surges 10%, Hits Record High On Merck's Positive Data For Covid Drug
Divi's Laboratories shares have so far this year advanced 38 per cent compared with Sensex which has gained 25 per cent.
-
Stocks To Watch: Bank of Baroda, Divi's Laboratories, SAIL, Affle India
Bank of Baroda reported a net profit of Rs 1,280.6 crore in the first quarter ended March 2021 against a loss of Rs 864.3 crore in the same quarter last year
-
Pharma Firm, India's Best-Performing Stock, Sees Wave of Optimistic Calls
In just about two weeks, at least four brokerages have raised their price targets on the shares of Divi's Laboratories -- one of the top producers of active pharmaceutical ingredients
-
Divi's Lab Shares Pare Gains, Trade Flat After US FDA Closes Out Warning Letter
The shares of Divi's Laboratories (Divi's Lab) pared early gains to trade 0.86% higher at Rs 1,018 on BSE at 3.10 pm. The scrip had hit 8% higher
-
Divi's Lab Shares Close 17% Higher As USFDA's Import Ban Set To Be Lifted From Vizag Plant
Divi's Laboratories has informed the NSE in a stock exchange filing that the USFDA will soon lift the import Alert 66-40 and will move to close out the warning letter issued to the company's unit-II at Vishakhapatnam.
-
Diwali Picks 2017: HDFC Securities' Five Stock Bets For Samvat 2074
For Samvat 2074, the top five stocks recommended by HDFC Securities are Bajaj Auto, Divi's Laboratories, Birla Corp, Persistent Systems and ICICI Prudential Life Insurance.
-
USFDA issues Warning Letter To Divis Labs For Vishakhapatnam Unit
The United States Food and Drug Administration (USFDA) has issued warning letter for the company's Unit-II at Vishakhapatnam, Divis Laboratories said in a BSE filing.
-
Trading Calls: Buy Pidilite Industries, Divi's Laboratories, Say Experts
Domestic brokerage Angel Broking in a note said domestic markets may see some consolidation or minor profit-taking moves but the undertone remains bullish.
-
Divis Lab Slumps 20% After US Regulator Issues Import Alert For Vizag Plant
Surjit Pal, pharma analyst at Prabhudas Lilladher, says Divis Lab shares could remain under pressure as its FY18 earnings would be hit due to the import alert.
-
Divi's Laboratories Files Response To US Regulator's Observations
Last month, the US regulator had made five observations after inspection of the company's manufacturing plant at Visakhapatnam.
-
Divi's Laboratories Slumps Over 30% In Just Two Days Over FDA Concerns
The Vizag plant is one of the biggest plants for Divi's. The company manufactures active pharmaceutical ingredients (APIs) and intermediates for generics among others at the Vizag manufacturing plant.
-
Divis Labs Q2 Net Down 24.6% At Rs 224 Crore
Divis Laboratories reported a 24.60 per cent dip in its standalone net profit to Rs 223.85 crore for the quarter ended September 30, 2016 mainly on account of increased expenses.
